Inventor · disambiguated record
Jordan Schecter
Also filed as: SCHECTER JORDAN · SCHECTER JORDAN MARK
1 granted patent·16 pending applications·10 citations·filing 2018–2025
34Inventor score
Top patents by PatentIndex Score
17 records- 0191US11618787B2Methods of treating high risk multiple myelomaJANSSEN BIOTECH INC·Filed 2018·Granted Apr 4, 2023·10 cites·12 claims
- 0269US2025000977A1Bcma-targeted car-t cell therapy for multiple myelomaLEGEND BIOTECH USA INC·Filed 2024·Application pending·0 cites
- 0368US2024358754A1Bcma-targeted car-t cell therapy for multiple myelomaLEGEND BIOTECH USA INC·Filed 2024·Application pending·0 cites
- 0468US2023340145A1Methods of Treating High Risk Multiple MyelomaJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 0561US2022204638A1Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their UsesJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 0657US2024000836A1Bcma-targeted car-t cell therapy for multiple myelomaJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 0757US2022265710A1Bcma-targeted car-t cell therapy for multiple myelomaJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 0857US2023270786A1Bcma-targeted car-t cell therapy for multiple myelomaJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 0954US2020392242A1Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their UsesJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 1052US2023277589A1Bcma-targeted car-t cell therapy for multiple myelomaJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 1147US2020405854A1Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their UsesJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 1246US2022275101A1Use of Approved Anti-CD38 Antibody Drug Product to Treat Light Chain AmyloidosisJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 1346US2020397896A1Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their UsesJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 1445US2020330594A1Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their UsesJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 1544US2024156962A1Bcma-targeted car-t cell therapy of multiple myelomaLEGEND BIOTECH USA INC·Filed 2023·Application pending·0 cites
- 1641US2025339527A1Bcma-targeted car-t cell therapy for multiple myelomaLEGEND BIOTECH USA INC·Filed 2025·Application pending·0 cites
- 1733US2025269024A1Bcma-targeted car-t cell therapy for multiple myelomaLEGEND BIOTECH USA INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jordan Schecter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →